These well-executed studies provided important molecular insights into a potentially effective therapeutic strategy by elevating phagocytosis against cancers by targeting the PD-1 pathway with PD-L1 protein or anti-PD-1 and sensitizing CT26 cells to anti-CD47 therapy [17]. This evidence concerns the gene CD47 and cancer.